Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Fortress Biotech, Inc.NASDAQ: FBIO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns positive
Q1 FY2026 free cash flow was $203.85M, compared with -$19.56M a year earlier. Trailing-twelve-month free cash flow was $157.64M. Over 3 fiscal years it compounded at -28.8% a year.
Context
- Free cash flow amounted to 104.0% of revenue in FY2025, down 61.1 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near $203.85M or moves back toward the trailing-twelve-month quarterly average of $39.41M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (65.78M) USD
- Year-over-year change
- +30.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (65.78M) | +30.9% |
| FY2024 | 2024-12-31 | (95.19M) | +30.2% |
| FY2023 | 2023-12-31 | (136.32M) | +25.3% |
| FY2022 | 2022-12-31 | (182.46M) | -37.3% |
| FY2021 | 2021-12-31 | (132.89M) | — |
Free Cash Flow vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 free cash flow of $157.64M is the largest of the 10 companies compared; the peer median is $42.36M.
- Its year-over-year change of +312.0% is the highest of 9, against a peer median of +1.1%.
- Free cash flow amounts to 238.3% of revenue for FBIO, versus a peer median of 804.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $157.64M | +312.0% | -28.8% | 238.3% | |
| LTM Mar 2026 | $124.96M | +0.9% | +25.5% | 1367.7% | |
| LTM Mar 2026 | $81.45M | -1.7% | +9.6% | — | |
| LTM Mar 2026 | $75.02M | +40.4% | +0.9% | — | |
| LTM Mar 2026 | $42.79M | -24.7% | -23.9% | — | |
| LTM Mar 2026 | $42.36M | +34.0% | +37.7% | — | |
| LTM Jun 2024 | $28.47M | — | -31.7% | 3489.8% | |
| LTM Mar 2026 | $19.37M | +1.3% | +7.6% | — | |
| LTM Mar 2026 | $14.8M | +143.9% | — | 5.8% | |
| LTM Apr 2026 | $4.36M | -16.5% | +18.7% | 241.6% | |
| Peer median (excluding FBIO) | $42.36M | +1.1% | +8.6% | 804.7% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (164.83M) | (213.91M) | (154.15M) | (120.86M) | (32.92M) |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.49M | 22.99M | 17.03M | 32.62M | 28.74M |
| Change in Working Capital | 36.37M | (715K) | (12.52M) | (8.13M) | (25.1M) |
| Accounts Receivables | 834K | (4.84M) | 12.52M | 4.47M | (19.33M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 43.31M | 8.35M | (24.38M) | (6.39M) | (7.97M) |
| Other Working Capital | 690K | (5.97M) | (4.61M) | (1.98M) | (2.6M) |
| Other Non-Cash Items | (14.36M) | 2.89M | 15.42M | 11.71M | (41.17M) |
| Operating Cash Flow | (116.54M) | (179.4M) | (128.23M) | (80.19M) | (65.78M) |
| Capital Expenditures | (16.35M) | (3.06M) | (8.1M) | (15M) | 0 |
| Acquisitions (Net) | 56.86M | (20M) | 0 | 0 | 8.96M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.78M) | (213K) | (2.04M) | 0 | 1.17M |
| Investing Cash Flow | 40.51M | (22.93M) | (2.1M) | (15M) | 10.12M |
| Debt Repayment | (9.64M) | 49.25M | (38.79M) | (7.33M) | (5.64M) |
| Common Stock Issued | 155.26M | 40.26M | 80.38M | 82.84M | 84.63M |
| Common Stock Repurchased | 0 | (1.11M) | 0 | 0 | (265K) |
| Dividends Paid | (8.78M) | (8.78M) | (8.77M) | (4.71M) | (664K) |
| Other Financing Activities | (4.8M) | (6.74M) | (529K) | (163K) | (360K) |
| Financing Cash Flow | 148.99M | 75.32M | 32.74M | 70.64M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.97M | (127.01M) | (97.59M) | (24.55M) | 21.79M |
| Free Cash Flow | (132.89M) | (182.46M) | (136.32M) | (95.19M) | (65.78M) |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.